Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LeonaBio, Inc. (LONA)

LeonaBio announces 500th patient enrolled in Phase 3 ELAINE-3 breast cancer trial

Neutral Impact 3 of 5 financing Written later

LeonaBio said it has enrolled the 500th subject in its Phase 3 ELAINE-3 trial of lasofoxifene with abemaciclib in ESR1-mutated metastatic breast cancer. The filing also sets the start of the exercise window for 23,031,494 Series A Common Warrants at $6.35 per share, which could bring about $146.2 million in cash if fully exercised, and states that the enrollment announcement triggers that window.

Key points

  • 500th subject enrolled in the ELAINE-3 Trial (NCT05696626), announced August 26, 2026
  • 23,031,494 Series A Common Warrants with an exercise price of $6.35 per share, issued in connection with the December 2025 Private Placement
  • Warrants become exercisable after the latest of June 30, 2026, this announcement, and FDA action on Eli Lilly's imlunestrant with abemaciclib, and no later than October 31, 2026
  • Full exercise would provide approximately $146.2 million; warrants expire no later than November 30, 2026

The filing

CompanyLeonaBio, Inc. (LONA)
Form8-K, current report
Filed with the SECAug 26, 2026, 4:05 PM ET
Accession number0001193125-26-368288

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.